top of page

welcome to
CLINICAL TRIALS DATA
The Clinical Trials Data website is designed as a comprehensive resource for key oncology trials. It presents information in a well-organized, user-friendly, and easily searchable format. The Trials included here include pivotal studies representing current standards of care as well as new emerging clinical trials, that can help shape future directions in oncology by expanding and improving treatment options. For each trial, the platform provides links to relevant conference abstracts, recent peer-reviewed publications, associated NCCN guideline references, and corresponding FDA labeling information. Our mission is to deliver accurate, evidence-based data in a concise, accessible format to support informed clinical decision-making.


IMforte: NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
First Posted 2021-10-25 Trial status Active, not recruiting Sponsor Hoffmann-La Roche Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Click here for details Peer-reviewed journal publication Efficacy and safety of first-line maintenance t
Dec 31, 2025


MATTERHORN: NCT04592913: Phase 3: Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC
First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for det
Dec 31, 2025


DESTINY-Breast09: NCT04784715: Phase 3: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer 1L
First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting II Free access Breast Cancer—Metastatic June 04, 2025 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast0
Dec 31, 2025


KEYNOTE-905 (EV-303): NCT03924895: Phase 3: Periop Pembro + Cystectomy or Periop Pembro + Enfortumab Vedotin + Cystectomy Versus Cystectomy Alone in (Cis ineligible) Muscle-invasive Bladder Cancer
First Posted 2019-04-23 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). 2023 ASCO Genitourinary Cancers Symposium Click here for details Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin
Dec 18, 2025


NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer
First Posted 2020-04-17 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Peer-reviewed journal publication Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer J Clin Oncol Sep 2025 PUBMED JCO NCCN FDA NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer (A Study of Osimertinib With or Without Chemotherapy Versus Che
Dec 15, 2025


NIVOPOSTOP: NCT03576417: Phase 3: Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc
Dec 15, 2025


TROPION-Breast01: NCT05104866: Phase 3: Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer, treated With 1-2 Prior LOT
First Posted 2021-11-03 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation ESMO 2023 (Annals of Oncology) abstract (LBA11) LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial October 2023 Click here for details AACR 2024 (Cancer Research) abstract (GS02-01) Ab
Dec 15, 2025


HER2CLIMB-05: NCT05132582: Phase 3: Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
First Posted 2021-11-24 Trial status Active, not recruiting Sponsor Seagen, a wholly owned subsidiary of Pfizer Abstract Presentation Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer December 10, 2025 Click here for details Peer-reviewed journal publication HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Tr
Dec 15, 2025


KEYNOTE-A18: NCT04221945: Phase 3: Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer
First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic
Dec 15, 2024


SU2C-SARC032: NCT03092323: Phase 2: A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
First Posted 2017-03-27 Trial status Active, not recruiting Sponsor Sarcoma Alliance for Research through Collaboration Abstract Presentation Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024 SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. Click here for details Peer-reviewed journal publication THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024 Safety and efficacy of pembrolizuma
Dec 15, 2024


KEYNOTE-A39 : NCT04223856: Phase 3: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
First Posted 2020-01-10 Trial status Active, not recruiting Sponsor Astellas Pharma Global Development, Inc. Abstract Presentation Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer ESMO - 11 Mar 2024 Click here for details Peer-reviewed journal publication Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 6, 2024 - N Engl J
Dec 15, 2023


ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63: NCT05633654: Phase 3: Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC
First Posted 2022-11-21 Trial status Recruiting Sponsor Gilead Sciences Abstract Presentation Peer-reviewed journal publication Press Release FDA NCCN NCT05633654: Phase 3: (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Hav
Dec 15, 2022


TOPAZ-1: NCT03875235: Phase 3: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer
First Posted 2019-03-14 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 ASCO Gastrointestinal Cancers Symposium Click here for details Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcita
Dec 15, 2022


KEYNOTE-522: NCT03036488: Phase 3: Study of Pembrolizumab (MK-3475) Plus Chemo vs Placebo Plus Chemo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy
First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm
Dec 15, 2021


KEYNOTE - 826: NCT03635567: Phase 3: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy First line Cervical cancer
First Posted 2018-08-17 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. June 3, 2023 2023 ASCO Annual Meeting Click here for details Peer-reviewed journal publication Pembrolizumab for Persistent, Recurrent, or Metastati
Dec 15, 2021


HER2CLIMB: NCT02614794: Phase 3: Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
First Posted 2015-11-25 Trial status Completed Sponsor Seagen Inc. Abstract Presentation Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis Late-breaking oral presentation, San Antonio Breast Cancer Symposium 2019; results subsequently published in NEJM (2020). Click here for details Peer-reviewed journal publication Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Dece
Dec 15, 2020
bottom of page